Form 8-K - Current report:
SEC Accession No. 0001437749-25-019803
Filing Date
2025-06-09
Accepted
2025-06-09 12:16:02
Documents
15
Period of Report
2025-06-05
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20250607_8k.htm   iXBRL 8-K 27475
2 EXHIBIT 99.1 ex_828383.htm EX-99.1 19830
7 nrxmed.jpg GRAPHIC 4616
  Complete submission text file 0001437749-25-019803.txt   210285

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20250605.xsd EX-101.SCH 4080
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20250605_def.xml EX-101.DEF 13855
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20250605_lab.xml EX-101.LAB 18277
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20250605_pre.xml EX-101.PRE 13887
17 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20250607_8k_htm.xml XML 4982
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

EIN.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 251033290
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)